IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19
- PDF / 1,386,284 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 1 Downloads / 139 Views
RESEARCH ARTICLE
Molecular Medicine
Open Access
IP‑10 and MCP‑1 as biomarkers associated with disease severity of COVID‑19 Yu Chen1†, Jinglan Wang2†, Chenxi Liu1†, Longxiang Su3†, Dong Zhang1, Junping Fan2, Yanli Yang2, Meng Xiao1, Jing Xie4, Yingchun Xu1, Yongzhe Li1*† and Shuyang Zhang5*†
Abstract Background: COVID-19 is a viral respiratory disease caused by the severe acute respiratory syndrome-Coronavirus type 2 (SARS-CoV-2). Patients with this disease may be more prone to venous or arterial thrombosis because of the activation of many factors involved in it, including inflammation, platelet activation and endothelial dysfunction. Interferon gamma inducible protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein 1-alpha (MIP1α) are cytokines related to thrombosis. Therefore, this study focused on these three indicators in COVID-19, with the hope to find biomarkers that are associated with patients’ outcome. Methods: This is a retrospective single-center study involving 74 severe and critically ill COVID-19 patients recruited from the ICU department of the Tongji Hospital in Wuhan, China. The patients were divided into two groups: severe patients and critically ill patients. The serum IP-10, MCP-1 and MIP1α level in both groups was detected using the enzyme-linked immunosorbent assay (ELISA) kit. The clinical symptoms, laboratory test results, and the outcome of COVID-19 patients were retrospectively analyzed. Results: The serum IP-10 and MCP-1 level in critically ill patients was significantly higher than that in severe patients (P
Data Loading...
